Transaction #2527 · Form 4 · 0001104659-25-102606
Viridian Therapeutics, Inc.\DE · Purchase · Common Stock
Viridian Therapeutics, Inc.\DE · Transacted October 23, 2025 · Filed October 27, 2025
What does this filing report?
An SEC Form 4 filing for Viridian Therapeutics, Inc.\DE records a purchase involving Common Stock on October 23, 2025. The reported quantity was 454,545. The filing date is October 27, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company CIK
- 0001590750
- Security type
- Non-derivative
- Acquisition type
- Purchase · Code P
- Quantity acquired
- 454,545
- Reported price
- 22
- Reference value
- 9,999,990
- Currency
- Currency not specified
- Ownership
- Indirect
- Holdings after transaction
- 3,914,458
- Ownership description
- Fairmount Healthcare Fund II LP
- SEC acceptance time
- Oct 27, 2025, 4:30 PM EDT
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Fairmount Healthcare Fund II L.P. ↗
Director · 10% owner
CIK 0001769651
- Fairmount Funds Management LLC ↗
Director · 10% owner
CIK 0001802528
- Fairmount Healthcare Fund II GP LLC ↗
Director · 10% owner
CIK 0001830382
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
The linked listing is identified separately from other current company listings.
Filing footnotes & remarks
- F1
- Fairmount Funds Management LLC ("Fairmount") and Fairmount Healthcare Fund II GP LLC ("Fairmount GP II") have voting power and investment power over the securities held by Fairmount Healthcare Fund II LP ("Fund II"). They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein.
Remarks
The Reporting Persons may each be deemed a director by deputization of Issuer by virtue of the fact that Tomas Kiselak serves on the board of directors of Issuer and is also a Managing Member of Fairmount Funds Management LLC.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.